drugset / Trial / NCT07080216
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
RandomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
Timeline
- Start
- 2025-09-23
- Primary completion
- 2027-08
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Gecacitinib | Unknown | — | — |
| Subject | ZG005 | Unknown | 20 mg/kg | Intravenous |